Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220642 | PMC |
http://dx.doi.org/10.1038/s41433-020-0943-8 | DOI Listing |
Ophthalmol Ther
December 2024
Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Introduction: The purpose of this study was to compare the growth factor concentrations in undiluted autologous platelet-rich plasma (APRP) and autologous serum (AS) eye drops.
Methods: This was a single-center, prospective trial conducted in a tertiary university hospital in Bangkok, Thailand. Ninety-six patients with moderate-to-severe dry eye disease, who were randomly assigned to receive either 100% APRP or 100% AS, were enrolled in the study.
Mo Med
December 2024
Neurologist specializing in headache treatment, Kansas City, Missouri.
This paper presents a new treatment modality, timolol 0.5% eye drops either topical to normal eyes or preferably by a compounded nasal spray for episodic use in patients with mild to moderate essential tremor. This would primarily be patients wishing to damp their tremors on certain occasions or who were not able to tolerate daily oral beta blockers.
View Article and Find Full Text PDFGraefes Arch Clin Exp Ophthalmol
November 2024
Novaliq GmbH, Heidelberg, Germany.
Purpose: This pooled analysis of two pivotal studies (ESSENCE-1 and ESSENCE-2) evaluated treatment effects of a water-free ciclosporin 0.1% solution in dry eye disease (DED) patients in the overall population and in subgroups according to sex, age, and baseline severity of disease.
Methods: In these randomized, multicenter, double-masked, vehicle-controlled studies patients received ciclosporin 0.
Mo Med
January 2024
Retired ophthalmologist, and editor of Missouri Medicine since 2000.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!